鼠抗人纤维蛋白单链抗体—低分子量尿激酶融合蛋白在？…

目的;构建鼠抗人纤维蛋白单链抗体－低分子量尿激酶融合蛋白,并在中国仓鼠卵巢细胞（ＣＨＯ）中高效表达。方法：应用重组ＤＮＡ技术,将编码尿激酶原信号肽的ＤＮＡ片段,与鼠抗人纤维蛋白单链抗体－低分子量尿激酶基因融合在一起,并插入真核表达载体ｐＭＪＫ３中,构建成重组质粒ｐＭＪＫ３Ｄ。通过细胞电击穿孔法,将该重组质中粒转染到中国仓鼠卵巢细胞二氢叶酸还原酶基因缺陷株中,转染细胞经选择培养基筛选。     

低分子量尿激酶与血纤蛋白粘附肽(12肽)融合表达及特性分析

人工合成血纤蛋白粘附肽（１２肽）ｃＤＮＡ，与低分子量单链尿激酶基因重组，获得血纤蛋白粘附肽与低分子量单链尿激酶的融合基因。将此融合基因重组入ｐＢＶ２２０表达载体并在大肠杆菌中表达，表达产物具有与天然尿激酶相同的抗原性和溶纤活性，同时兼具血纤蛋白粘附肽（１２肽）的抗血纤蛋白单体聚合的活性     

可溶性E—选择素cDNA基因克隆及其真核表达

从ｐＵＣ１８／Ｅ－选择素重组质粒经ＰＣＲ扩增得到可溶性Ｅ－选择素ｃＤＮＡ基因，将此基础插入到痘苗病毒表达载体ｐＪＳＡ１１７５的Ｓｍａ Ｉ位点，构建了正向表达质粒ｐＪＳＡ１１７５．可溶性Ｅ－选择素，采用脂质供共转染的方法，将上述质粒转染ＴＫ＾－１４３细胞。     

低分子量尿激酶与血纤蛋白粘附肽（12肽）融合表达及特性…

人工合成血纤蛋白粘附肽（１２肽）ｃＤＮＡ，与低分子量单链尿激酶基因重，获得血纤蛋白粘附肽与低分子量单链尿酶的融合基因。将此融合基因重组入ｐＢＶ２２０表达载体并在大肠杆菌中表达，表达产物具有与天然尿激酶相同的抗原性和溶性活性，同时人血纤蛋白附肽（１２肽），的抗血纤收白单体聚合的活性。     

人白介素6在CHO细胞中的克隆与表达

本研究通过引物设计、转译优化、ＤＮＡ体外重组等技术，构建了ｐＳＶ２·ＩＬ６重组质粒，利用磷酸钙共沉淀法转染中国仓鼠卵巢细胞二氢叶酸还原酶缺陷型（ＣＨＯｄｈｆｒ－）株，经选择培养基筛选及逐渐提高甲氨蝶呤（ＭＴＸ）的浓度加压基因共扩增法，获得一株稳定表达人ＩＬ６的细胞株，用ＩＬ６依赖的杂交瘤细胞株７ＴＤ１测定细胞上清液的ＩＬ６生物学活性为１．９×１０５Ｕ／（１０６细胞·ｄ）。     

水蛭素12肽与低分子量尿激酶融合基因的构建和表达

目的：旨在获得既能抗栓又能溶栓的双功能蛋白，并在大肠杆菌中表达。方法：化学合成水蛭素１２肽基因编码序列，通过ＤＮＡ重组技术将水蛭素１２肽基因片段连接到低分子量尿激酶ｃＤＮＡ片段５′端，构建成融合基因，结果：构建了水蛭素１２肽与低分子量尿激酶的融合基因，在大肠杆菌中获得表达，重组融合蛋白具有溶栓与抗栓双功能。结论：运用ＤＮＡ重组技术可将两种不同功能的蛋白合理地融合在一起，使其具有溶纤活性和抗凝活性。     

二硫键稳定的抗肝癌人源化单链抗体—突变体人TNFα融合基因在CHO（dhfr^—）细胞中的表达

目的：提高抗肝癌靶向人肿瘤坏死因子（hScFv25-hTNFα)的稳定性和杀伤活性,构建二硫键稳定的抗肝癌人源化单链抗体－突变体人TNFα融合基因（ds-ScFv-hTNFα）,并在CHO细胞中表达。方法：常规构建ds-ScFv-hTNFα融合基因,并克隆入真核表达载体pCI(dhfrl）,磷酸钙共沉淀法转染中国仓鼠卵巢细胞株（CHO－dhfr^-）,甲氨蝶呤（MTX）高压筛选高表达细胞株,免疫荧光染色和MTT法检测重组蛋白的抗体和突变体hTNFα的双重活性。结果：目的基因在CHO（dhfr^－）中获得了表达,表达产物具有抗体和突变体hTNFα的双重活性,且稳定性得到大幅度提高,达到4℃放置4个月活性无明显下降。结论：抗肝癌人源化ds-ScFv-hTNFα融合基因在CHO细胞中获得功能性表达,为进一步的临床应用研究奠定了基础。     

人表皮细胞生长因子基因真核表达质粒pcDNA3—hEGF的构建

目的：构建人表皮细胞生长因子（ｈＥＧＦ）基因真核表达质粒，为深入研究ｈＥＧＦ在组织修复中的分子调节机制及临床应用提供物质基础。方法：含ｈＥＧＦ ｃＤＮＡ的ｐＵＣ１８－ｈＥＧＦ质粒于大肠杆菌ＪＭ１０９内扩增；提纯及纯化ｐＵＣ１８－ｈＥＧＦ质粒；经ＤＮＡ序列分析其所含ｈＥＧＦ ｃＤＮＡ；限制性酶切ｈＥＧＦ ｃＤＮＡ片段，连接酶连接到真核表达质粒ｐｃＤＮＡ３－ｎｅｏ内，克隆出真核表达质粒ｐｃＤＮＡ３－ｈ     

我国登革2型病毒43株PrM-E基因的构建及其在哺乳动物细胞中的表达

目的：构建我国登革２ 型病毒４３ 株（Ｄ２－４３）的ＰｒＭ－Ｅ基因片段,观察其在哺乳动物细胞中的表达。方法：采用ＲＴ－ＰＣＲ和分子克隆技术构建ＰｒＭ－Ｅ基因片段,包括编码ＰｒＭ 的信号肽序列、完整的ＰｒＭ 蛋白和去除羧基端跨膜疏水区部分氨基酸的９７．８％ Ｅ蛋白的基因片段。用电穿孔法将构建的含有ＰｒＭ－Ｅ基因的ｐＣＭＶ－ＭＥ真核重组质粒导入哺乳动物细胞中进行表达。采用蛋白印迹和间接免疫荧光法对表达产物进行特异性鉴定。结果与结论：构建的ＰｒＭ－Ｅ基因全长２ ０１９个核苷酸,序列分析证明其核苷酸序列是正确的。ＰｒＭ－Ｅ基因在ＢＨＫ－２１ 细胞中获得高效表达,表达蛋白可与Ｄ２－４３ 多克隆抗体起特异反应,且表达蛋白主要位于细胞浆中。     

反义bcr／ab1重组逆转录病毒表达载体的构建及其转染对K562细胞系的影响

用逆转录聚合酶链反应技术从Ｋ５６２细胞系中扩增出ｂｃｒ／ａｂ１融合区２５３ｂｐＤＮＡ片段，经反复连接与克隆，得到含同方向串联的２、３和４个拷贝的该融合基因片段的克隆载体ｐＵＣｓ。这些片段分别反向连接到逆转录病毒表达载体ｐＤＯＲｎｅｏ。ＤＮＡ序列分析、限制性内切酶分析和菌落原位杂交证实：不同拷贝数的ｂｃｒ／ａｂ１融合区基因片段已反向插入ｐＤＯＲｎｅｏ。利用脂质体介导，将重组质粒导入Ｋ５６２细胞系后，观察到转染细胞的增殖明显被抑制     

The acutely limping child

Acute limping may be the result of multiple pathologies in children. The differential diagnosis varies based on the age of the child. Irrespective of age, the initial imaging work-up includes AP and frog leg radiographs of the pelvis and ultrasound; MRI may sometimes be helpful. In children less than 3 years, infections and trauma are most frequent. MRI is the imaging modality of choice when osteomyelitis is clinically suspected. Between the ages of 3 and 10 years, transient synovitis of the hip and Legg-Calvé-Perthes disease are main considerations but infection, inflammation and focal bony lesions are also considered. In children over 10 years, slipped capital femoral epiphysis also is considered.     

High Intensity Interval Training:New Insights

KEY POINTS ·High-intensity interval training(HIT)is characterized by repeated sessions of relatively brief，intermittent exercise.often performed with an“a11 out”effort or at an intensity close to that which elicits peak oxygen uptake(i.e.，≥90%of VO2 peak).     

Developmental validation of the PowerPlex(®) ESI 16 and PowerPlex(®) ESI 17 Systems: STR multiplexes for the new European standard

In response to the ENFSI and EDNAP groups’ call for new STR multiplexes for Europe, Promega^® developed a suite of four new DNA profiling kits. This paper describes the developmental validation study performed on the PowerPlex^® ESI 16 (European Standard Investigator 16) and the PowerPlex^® ESI 17 Systems. The PowerPlex^® ESI 16 System combines the 11 loci compatible with the UK National DNA Database^®, contained within the AmpFlSTR^® SGM Plus^® PCR Amplification Kit, with five additional loci: D2S441, D10S1248, D22S1045, D1S1656 and D12S391. The multiplex was designed to reduce the amplicon size of the loci found in the AmpFlSTR^® SGM Plus^® kit. This design facilitates increased robustness and amplification success for the loci used in the national DNA databases created in many countries, when analyzing degraded DNA samples. The PowerPlex^® ESI 17 System amplifies the same loci as the PowerPlex^® ESI 16 System, but with the addition of a primer pair for the SE33 locus. Tests were designed to address the developmental validation guidelines issued by the Scientific Working Group on DNA Analysis Methods (SWGDAM), and those of the DNA Advisory Board (DAB). Samples processed include DNA mixtures, PCR reactions spiked with inhibitors, a sensitivity series, and 306 United Kingdom donor samples to determine concordance with data generated with the AmpFlSTR^® SGM Plus^® kit. Allele frequencies from 242 white Caucasian samples collected in the United Kingdom are also presented. The PowerPlex^® ESI 16 and ESI 17 Systems are robust and sensitive tools, suitable for the analysis of forensic DNA samples. Full profiles were routinely observed with 62.5 pg of a fully heterozygous single source DNA template. This high level of sensitivity was found to impact on mixture analyses, where 54–86% of unique minor contributor alleles were routinely observed in a 1:19 mixture ratio. Improved sensitivity combined with the robustness afforded by smaller amplicons has substantially improved the quantity of data obtained from degraded samples, and the improved chemistry confers exceptional tolerance to high levels of laboratory prepared inhibitors.     

Knee injury and Osteoarthritis Outcome Score (KOOS) - validation of a Swedish version

The Knee injury and Osteoarthritis Outcome Score (KOOS) is a self-administered instrument measuring outcome after knee injury at impairment, disability, and handicap level in five subscales. Reliability, validity, and responsiveness of a Swedish version was assessed in 142 patients who underwent arthroscopy because of injury to the menisci, anterior cruciate ligament, or cartilage of the knee. The clinimetric properties were found to be good and comparable to the American version of the KOOS. Comparison to the Short Form-36 and the Lysholm knee scoring scale revealed expected correlations and construct validity. Item by item, symptoms and functional limitations were compared between diagnostic groups. High responsiveness was found three months after arthroscopic partial meniscectomy for all subscales but Activities of Daily Living.     

Bronchial stump fistula :treatment with covered retrievable hinged metallic stents-preliminary clinical experience

Objective To evaluate the preliminaily clinical efficacy and retrievability of a retrievable hinged covered metallic stent in the treatment of the bronchial stump fistula （BSF）. Methods Between April 2003 and March 2005, 8 patients with bronchial stump fistula after pneumonectomy or lobectomy were treated with two types （A and B） of retrievable hinged covered metallic stents. Type A stent was placed in 6 patients and type B in 2 under fluoroscopic guidance. The stent was removed with a retrieval set when BSF was healed or complications occurred. Results Stent placement in the bronchial tree was technically successful in all patients, without procedure-related complications. Immediate closure of the BSF was achieved in all patients after the procedure. Stents were removed from all patients but one. Removal of the stents was difficult in two patients due to tissue hyperplasia. Patients were followed up for 6 - 21 months. Placement of the stents remained stable in all patients except one due to severe cough. Permanent closure of BSF was achieved in 7 （87.5%） of 8 patients. Conclusion Use of a retrievable hinged covered expandable metallic stent is a simple, safe, and effective procedure for closure of the BSF. Retrieval of the stent seems to be feasible. （J Intervent Radiol, 2007, 16： 253-257）     

Die rechtsmedizinische Identifizierung — Bedeutung und Beweiswert —

Zusammenfassung Bei der rechtsmedizinischen Identifizierung kann die Identität im strengen Sinn allenfalls bei lebenden Personen festgestellt werden; sonst läßt sich nur von Teilen auf das Ganze (vom Untersuchungsobjekt auf die Person) schließen, wobei die verschiedenen Merkmale des Untersuchungsobjektes entsprechend der Hdufigkeit ihres Vorkommens eine unterschiedliche Beweiskraft haben. Bei der Schädelidentifizierung mit Hilfe moderner photographischer oder elektronischer Superprojektionsverfahren ergeben sich unter Berücksichtigung der Weichteildicken so viele (fiktive) Vergleichspunkte, daß bei geeignetem Vergleichsmaterial (Photographien) Identität wegen der Vielzahl übereinstimmender Bezugspunkte in den meisten Fällen evident ist.     

Imaging of abdominal nodal spread in malignant disease

This is a review of the role of imaging procedures for the assessment of abdominal and pelvic lymph nodes. The diagnosis of malignant lymphatic spread is rarely the sole purpose of imaging, because it is usually part of a general abdominal examination, most frequently with CT or US, or increasingly with MRI. These studies are often requested in order to obtain information about the situation to be encountered during surgery, or to alert the surgeon to irresectability or to unexpected metastases outside the initially planned area of exploration. In most surgically treated tumours the role of imaging for preoperative staging is limited, due either to its insufficient sensitivity or because the initial treatment is independent of the lymph node stage. Imaging is commonly used to verify treatment response to chemo- or radiotherapy and for follow-up.Correspondence to: S. Delorme